3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid has been researched along with Paralysis in 1 studies
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist
Paralysis: A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakshi, R | 1 |
| Faden, AI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dextromethorphan Versus Placebo for Neuropathic Pain[NCT00001344] | Phase 2 | 129 participants | Interventional | 1993-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Paralysis
| Article | Year |
|---|---|
Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis.
Topics: Animals; Binding, Competitive; Dextrorphan; Dynorphins; Hindlimb; Male; Morphinans; Paralysis; Pepti | 1990 |